Mechanisms of the actions of aromatase inhibitors 4-hydroxyandrostenedione, fadrozole, and aminoglutethimide on aromatase in JEG-3 cell culture

https://doi.org/10.1016/S0960-0760(97)00072-1Get rights and content

Abstract

Selective inhibition of estrogen production with aromatase inhibitors has been found to be an effective strategy for breast cancer treatment. Most studies have focused on inhibitor screening and in vitro kinetic analysis of aromatase inhibition using placental microsomes. In order to determine the effects of different inhibitors on aromatase in the whole cell, we have utilized the human choriocarcinoma cell line, JEG-3 in culture to compare and study three classes of aromatase inhibitors, 4-hydroxyandrostenedione, fadrozole (CGS 16949A), and aminoglutethimide. Fadrozole is the most potent competitive inhibitor and aminoglutethimide is the least potent among the three. However, stimulation of aromatase activity was found to occur when JEG-3 cells were preincubated with aminoglutethimide. In contrast, 4-OHA and fadrozole caused sustained inhibition of aromatase activity in both JEG-3 cells and placental microsomes, which was not reversed even after the removal of the inhibitors. 4-OHA bound irreversibly to the active site of aromatase and caused inactivation of the enzyme which followed pseudo-first order kinetics. However, 4-OHA appears to be metabolized rapidly in JEG-3 cells. Sustained inhibition of aromatase induced by fadrozole occurs by a different mechanism. Although fadrozole bound tightly to aromatase at a site distinct from the steroid binding site, the inhibition of aromatase activity by fadrozole does not involve a reactive process. None of the inhibitors stimulated aromatase mRNA synthesis in JEG-3 cells during 8 h treatment. The stimulation of aromatase activity by AG appeared to be due to stabilization of aromatase protein. According to these results, 4-OHA and fadrozole would be expected to be more beneficial in the treatment of breast cancer patients than AG. The increase in aromatase activity by AG may counteract its therapeutic effect and might be partially responsible for relapse of breast cancer patients from this treatment.

References (32)

  • A.M.H. Brodie et al.

    Aromatase Inhibitors and Breast Cancer

    Seminars in Oncology

    (1996)
  • A.M.H. Brodie et al.

    The effect of an aromatase inhibitor, 4-hydroxy-4-androstene-3,17-dione, on estrogen-dependent processes in reproduction and breast cancer

    Endocrinol.

    (1977)
  • R. Steele et al.

    In vitro and in vivo studies demonstrating potent and selective estrogen inhibition with the nonsteroidal aromatase inhibitor FadrozoleA

    Steroids

    (1987)
  • R. Cash et al.

    Amino glutethimide as an inhibitor of adrenal steroidogenesis mechanism of action and therapeutic trial

    J. Chin. Endocrinol. Metab.

    (1967)
  • M. Dowsett et al.

    Endocrine changes associated with relapse in advanced breast cancer patients on aminoglutethimide therapy

    J. Clin. Endocr. Metab.

    (1984)
  • R.S. Bahn et al.

    Characterization of steroid production in cultured human choriocarcinoma cells

    J. Clin. Endocrinol. Metab.

    (1981)
  • Cited by (46)

    • Tributyltin and triphenyltin induce 11β-hydroxysteroid dehydrogenase 2 expression and activity through activation of retinoid X receptor α

      2020, Toxicology Letters
      Citation Excerpt :

      The efficacy of 5 μg/mL CHX in blocking protein synthesis in JEG-3 cells was tested by assessment of 50 nM Bex-induced 11β-HSD2 protein levels and was found to totally abolish the de novo 11β-HSD2 protein synthesis (data not shown). Additionally, this concentration of CHX was shown earlier to significantly inhibit protein synthesis in JEG-3 cells and was utilized to study the effect of angiotensin II on 11β-HSD2 expression under conditions of translational inhibition (Lanz et al., 2003; Yue and Brodie, 1997). To study whether upregulation of 11β-HSD2 mRNA results from enhanced gene transcription, cells were simultaneously incubated with 50 nM organotins or Bex and the transcriptional inhibitor Act D. Inhibition of transcription significantly prevented the increase of 11β-HSD2 mRNA upon exposure to TBT, TPT and Bex compared to control (Fig. 5B).

    • The steroid metabolite 16(β)-OH-androstenedione generated by CYP21A2 serves as a substrate for CYP19A1

      2017, Journal of Steroid Biochemistry and Molecular Biology
      Citation Excerpt :

      In contrast, additional hydroxylations of A4 or T have been shown to dramatically affect binding properties of CYP19A1. For example, it was already shown that 4-hydroxy-androstenedione, which is used for the treatment of breast cancer, irreversibly binds to CYP19A1 [36,37]. In order to investigate whether 16bOHA4 is metabolized by CYP19A1 we performed a reconstituted in vitro assay, consisting of recombinantly expressed and purified human CYP19A1 and human CPR.

    • Evaluation of a bioluminescent mouse model expressing aromatase PII-promoter-controlled luciferase as a tool for the study of endocrine disrupting chemicals

      2010, Toxicology and Applied Pharmacology
      Citation Excerpt :

      Primary cell cultures, although more relevant for mechanistic studies and environmental/species relevance than cancer cell lines, have as disadvantage that they are difficult to obtain, maintain and standardize, and loss of gene expression may occur over time. In vitro studies in human placental microsomes or cell lines have shown that aromatase may be inhibited or induced by various environmental chemicals, medications or naturally occurring dietary compounds (Mason et al., 1987; Ibrahim and Abul-Hajj, 1990; Campbell and Kurzer, 1993; Yue and Brodie, 1997; Drenth et al., 1998; Le Bail et al., 1998; Vinggaard et al., 2000; Saarinen et al., 2001; Andersen et al., 2002; Sanderson et al., 2002, 2004; Fernandez-Canton et al., 2003; Ohno et al., 2004; Heneweer et al., 2005; Letcher et al., 2005; Sanderson, 2006; He et al., 2008). For example, various dietary (iso)flavonoids induce (genistein, quercetin) or inhibit (chrysin, apigenin) human aromatase activity (Sanderson et al., 2004) and anti-breast cancer medications, such as fadrozole, letrozole and anastrozole (Miller and Dixon, 2000), as well as various pesticides (Vinggaard et al., 2000; Sanderson et al., 2002), are highly potent inhibitors of its catalytic activity.

    • Cell density is a critical determinant of aromatase expression in adipose stromal cells

      2010, Journal of Steroid Biochemistry and Molecular Biology
    • In situ hybridization to detect spatial gene expression in medaka

      2009, Ecotoxicology and Environmental Safety
    View all citing articles on Scopus
    View full text